Viromed Medical AG, a medical technology company specializing in cold plasma technology, has entered into an exclusive global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH. The agreement focuses on combining Viromed's PulmoPlas® platform with NEBU-TEC's nebulization technology for veterinary applications, with an initial emphasis on treating pulmonary diseases in horses.
The partnership grants NEBU-TEC worldwide exclusive distribution rights for veterinary uses of the combined technology. This collaboration aims to strengthen the international commercialization of PulmoPlas® and open new therapeutic applications for respiratory diseases in animals. The market launch of PulmoPlas® vet is scheduled for later in 2026, and no regulatory approval is required for this veterinary application.
NEBU-TEC, a globally active medical technology company with 30 years of experience in aerosol medicine, develops and manufactures state-of-the-art inhalation devices for both human and veterinary medicine. Under the partnership, Viromed's cold plasma technology will be integrated into NEBU-TEC's inhalation and nebulization solutions. The devices used are Class IIa medical devices under the EU Medical Device Regulation (MDR), which also allows for future human medical applications in combination with PulmoPlas® med.
Viromed CEO Uwe Perbandt stated: "The partnership with NEBU-TEC represents an important step in the international commercialization of our PulmoPlas® platform. Combining our cold plasma technology with NEBU-TEC's nebulization expertise opens up new fields of application in veterinary medicine and, going forward, also for applications in human medicine."
Eike Kern, Managing Director of NEBU-TEC, emphasized: "The combination of inhalative application and cold plasma opens up new therapeutic possibilities. By bringing together complementary technologies, we are creating innovative and safe concepts for the treatment of both animals and humans – effective, safe and forward-looking."
The equine market, particularly in Europe and equestrian sports, faces significant demand for effective solutions for respiratory diseases, which affect a substantial proportion of the horse population. This partnership addresses that need and positions Viromed to expand its strategic collaborations in cold plasma technology while laying the groundwork for entering additional international markets and applications.
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the distribution of cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. The company serves a broad customer base in the DACH region and beyond. NEBU-TEC, headquartered in Elsenfeld, offers nebulization solutions for professional healthcare facilities and home use.
For more information, visit Viromed Medical AG or NEBU-TEC.
